Catalog No.S2903 Synonyms: COX-189
Molecular Weight(MW): 293.72
Lumiracoxib is a novel, selective COX-2 inhibitor with Ki of 0.06 μM. It also inhibits COX1 with Ki of 3 μM.
3 Customer Reviews
(A) Western blot analysis of MITF expression in MelIM. One representative experiment out of two is shown. (B) Proliferation of MelIM cells under diclofenac or lumiracoxib (0.1 mM) for 3 vs. 30 days. Results are given as percentage of untreated controls.
Cancer Lett, 2019, 442:453-463. Lumiracoxib purchased from Selleck.
Blood concentration-time profiles for lumiracoxib following single oral administration at 10 mg/kg to (a) Hu-FRGTM mice (n = 3) and (b) to Mu-FRGTM mice (n = 3). Symbols represent concentration-time profiles from individual animals.
Biochem Pharmacol, 2017, 135:139-150. Lumiracoxib purchased from Selleck.
Purity & Quality Control
Choose Selective COX Inhibitors
|Description||Lumiracoxib is a novel, selective COX-2 inhibitor with Ki of 0.06 μM. It also inhibits COX1 with Ki of 3 μM.|
Lumiracoxib has an IC50 of 0.14 μm in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 μm (HEK 293 cells transfected with human COX-1). In a human whole blood assay, IC50 values for Lumiracoxib are 0.13 μM for COX-2 and 67 μM for COX-1 (COX-1/COX-2 selectivity ratio 515). 
|In vivo||Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety. Lumiracoxib is rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h. Efficacy of Lumiracoxib in rat models of hyperalgesia, oedema, pyresis and arthritis is dose-dependent and similar to diclofenac. However, consistent with its low COX-1 inhibitory activity, Lumiracoxib at a dose of 100 mg/kg orally causes no ulcers and is significantly less ulcerogenic than diclofenac. |
|In vitro||DMSO||59 mg/mL (200.87 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00350155||Completed||Drug: Lumiracoxib||Healthy Volunteers||Novartis||May 2006||Phase 4|
|NCT00348491||Completed||Drug: Lumiracoxib||Pain||Novartis Pharmaceuticals|Novartis||February 2006||Phase 4|
|NCT00267176||Completed||Drug: lumiracoxib||Osteoarthritis|Controlled Hypertension||Novartis Pharmaceuticals|Novartis||November 2005||Phase 4|
|NCT00170872||Completed||Drug: Lumiracoxib||Osteoarthritis|Rheumatoid Arthritis||Novartis||November 2004||Phase 3|
|NCT00145301||Completed||Drug: Lumiracoxib||Osteoarthritis||Novartis||September 2004||Phase 3|
|NCT00475800||Completed||Drug: Lumiracoxib||Osteoarthritis||Novartis||January 2004||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.